News articles about Boston Scientific Corporation (NYSE:BSX) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Boston Scientific Corporation earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 48.9010352355399 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Know the Secrets in Technical Analysis of Boston Scientific Corporation (BSX) – Wall Street Morning (wallstreetmorning.com)
- Investors watchful Oversold Stock: Boston Scientific Corporation (BSX) stock RSI shifts below 30 – Voice Of Analysts (analystsbuzz.com)
- Contrasting Boston Scientific Corporation (BSX) and Its Peers (americanbankingnews.com)
- Boston Scientific Corporation (BSX) EVP Timothy A. Pratt Sells 10,000 Shares (americanbankingnews.com)
- Analyzing Boston Scientific Corporation (BSX) and Its Peers (americanbankingnews.com)
Boston Scientific Corporation (NYSE BSX) opened at $27.86 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The firm has a market cap of $37.68 billion, a P/E ratio of 22.49, a PEG ratio of 2.12 and a beta of 1.00.
Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the business posted $0.27 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. equities analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current year.
A number of equities research analysts have issued reports on BSX shares. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research note on Wednesday, July 12th. Cowen and Company reiterated an “outperform” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research note on Monday, July 17th. BidaskClub lowered Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, Oppenheimer Holdings, Inc. set a $29.00 price target on Boston Scientific Corporation and gave the stock a “hold” rating in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $30.77.
In other news, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific Corporation stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the transaction, the executive vice president now directly owns 164,681 shares in the company, valued at $4,647,297.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total value of $416,485.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 508,864 shares of company stock valued at $14,581,669. 0.74% of the stock is owned by company insiders.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.